SLC5A2 and congestive heart failure: Sodium‐glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of worsening heart failure and mortality in patients with chronic heart failure across the full spectrum of left ventricular ejection fraction (LVEF).17, 18